Research-Grade Delta Sleep-Inducing Peptide Overview
DSIP Magnus Pharmaceuticals is a delta sleep-inducing peptide manufactured to laboratory research standards. This nonapeptide compound, originally isolated from rabbit cerebral venous blood during natural sleep phases, demonstrates unique neuropeptide characteristics in experimental models. Stroid UK Shop recognise DSIP as a valuable tool for investigating sleep-wake cycle mechanisms and circadian rhythm modulation in controlled laboratory environments.
Scientific Investigation Applications
Research teams investigate DSIP for its distinctive effects on sleep architecture and neurotransmitter pathways in animal models. Studies examine how this peptide modulates GABA receptor activity and influences hypothalamic-pituitary axis function during circadian research. Scientists also evaluate DSIP’s potential role in stress response mechanisms and its interaction with endogenous sleep-promoting factors. DSIP peptide research encompasses neurological studies investigating sleep disorders, circadian biology, and neuroprotective mechanisms in laboratory settings.
Technical Specifications
| Parameter | Value |
|---|---|
| Sequence | Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu |
| Molecular Weight | 849 g/mol |
| CAS Number | 62568-57-4 |
| Storage | -20°C lyophilised, 2-8°C reconstituted |
| Purity | Verify with supplier documentation |
| Manufacturer | Magnus Pharmaceuticals |
The peptide requires careful handling under sterile conditions and appropriate storage temperatures to maintain structural integrity throughout research protocols. Reconstitution should follow standard laboratory procedures for peptide preparation.
Research Compliance and Laboratory Use
Magnus Pharmaceuticals DSIP joins comprehensive peptide research portfolios alongside selective androgen receptor modulators and bioactive peptide compounds for multi-faceted research programs. This compound enables investigators to examine sleep physiology, neurochemical signaling pathways, and circadian rhythm regulation in appropriate research models. DSIP Magnus Pharmaceuticals is intended exclusively for in-vitro research applications and is not approved for human consumption, therapeutic use, or any application outside controlled laboratory investigations.
